Zygolide® (pergolide tablets)

Zygolide® is indicated for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease) in horses.
 
Zygolide® should be administered orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. 
 
Pack size(s): 60ct, 160 ct
Documents: Package insert get_app SDS get_app

Important safety information

As with all drugs, side effects may occur. Zygolide® (pergolide tablets) is for use in horses only. Zygolide® has not been evaluated in breeding, pregnant or lactating horses. Treatment with Zygolide® may cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changes also may be observed. Zygolide® tablets should not be crushed due to the potential for increased human exposure. Pregnant or lactating women should wear gloves when administering this product. Zygolide® is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Keep Zygolide® in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten pergolide tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest Zygolide® tablets. Refer to the prescribing information for complete details or visit www.dechra‐ us.com.

 

Got More Questions?

keyboard_arrow_up